scholarly journals Rebound Thymic Hyperplasia Detected by 18F-FDG PET/CT After Radioactive Iodine Ablation Therapy for Thyroid Cancer

Thyroid ◽  
2014 ◽  
Vol 24 (11) ◽  
pp. 1636-1641 ◽  
Author(s):  
Tae Joo Jeon ◽  
Yong Sang Lee ◽  
Jae-Hoon Lee ◽  
Hang Seok Chang ◽  
Young Hoon Ryu
Diagnostics ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1417
Author(s):  
Cristina Ferrari ◽  
Giulia Santo ◽  
Rossella Ruta ◽  
Valentina Lavelli ◽  
Dino Rubini ◽  
...  

Differentiated thyroid cancer (DTC) represents the most common thyroid cancer histotype. Generally, it exhibits a good prognosis after conventional treatments; nevertheless, about 20% of patients can develop a local recurrence and/or distant metastasis. In one-third of advanced DTC, the metastatic lesions lose the ability to take up iodine and become radioactive iodine-refractory (RAI-R) DTC. In this set of patients, the possibility to perform localized treatments should always be taken into consideration before the initiation of systemic therapy. In the last decade, some multi-tyrosine kinase inhibitor (MKI) drugs were approved for advanced DTC, impacting on patient’s survival rate, but at the same time, these therapies have been associated with several adverse events. In this clinical context, the role of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography ([18F]FDG PET/CT) in the early treatment response to these innovative therapies was investigated, in order to assess the potentiality of this diagnostic tool in the early recognition of non-responders, avoiding unnecessary therapy. Herein, we aimed to present a critical overview about the reliability of [18F]FDG PET/CT in the early predictive response to MKIs in advanced differentiated thyroid cancer.


2020 ◽  
Vol 31 ◽  
pp. S1089
Author(s):  
A. Jannin ◽  
L. Lamartina ◽  
C. Moutarde ◽  
M. Djennaoui ◽  
G. Lion ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Luca Foppiani ◽  
Simona Sola ◽  
Manlio Cabria ◽  
Gianluca Bottoni ◽  
Arnoldo Piccardo

Over 50% of patients with papillary thyroid carcinoma (PTC) have cervical lymph-node metastasis on diagnosis, and up to 30% show nodal recurrence after surgery plus radioactive iodine (131I) (RAI) therapy. The combination of ultrasonography (US) and fine-needle aspiration cytology (FNAC) and the measurement of thyroglobulin (Tg) in washout fluid are cornerstones in the diagnosis of nodal metastasis. In the absence of anti-Tg antibodies, unstimulated serum thyroglobulin (Tg) levels are generally a reliable marker of recurrent disease, and 18F-FDG positron emission tomography (PET)/computed tomography (CT) plays an important role in the imaging work-up. We report the case of a 65-year-old man evaluated for a large multinodular goitre which caused compressive symptoms; the dominant nodule in the left lobe presented suspicious features on US. Thyroid function showed subclinical hypothyroidism, calcitonin was normal, serum thyroglobulin levels were low, and anti-thyroid antibodies were absent. The prevalent left nodule showed an intense uptake on 18F-FDG PET/CT but proved benign at FNAC. On the basis of the suspicious clinical and imaging features, total thyroidectomy was performed. Histology revealed a tall-cell variant of PTC with scattered expression of Tg and diffuse high expression of cytokeratin (CK) 19; RAI therapy was performed. Within 6 years of surgery, left laterocervical lymph-node recurrence was twice detected (first at levels II and III, then at levels IV and VI) by US and 18F-FDG-PET/CT and was confirmed by FNAC. Tg levels in the washout fluid proved clearly diagnostic of metastasis only in the second, larger, recurrence, whereas serum Tg levels (in the absence of anti-Tg antibodies) always remained undetectable on L-thyroxine therapy. Surgery was performed on both recurrences, and histology confirmed lymph-node metastasis of PTC. Immunohistochemical expression of Tg and CK 19 was similar to that of the primary tumour. No further relapses have occurred to date. Posttherapy (surgery and RAI) unstimulated serum Tg levels may not be a reliable marker of nodal recurrence in patients with differentiated thyroid cancer (DTC) that produces low amounts of Tg.


2012 ◽  
Vol 37 (9) ◽  
pp. e234-e236 ◽  
Author(s):  
Camila Mosci ◽  
I. Ross McDougall ◽  
R. Brooke Jeffrey ◽  
Andrei Iagaru

Sign in / Sign up

Export Citation Format

Share Document